Document Detail

Donepezil in Alzheimer's disease: what to expect after 3 years of treatment in a routine clinical setting.
MedLine Citation:
PMID:  17312368     Owner:  NLM     Status:  MEDLINE    
BACKGROUND/AIMS: Clinical short-term trails have shown positive effects of donepezil treatment in patients with Alzheimer's disease. The outcome of continuous long-term treatment in the routine clinical settings remains to be investigated. METHODS: The Swedish Alzheimer Treatment Study (SATS) is a descriptive, prospective, longitudinal, multicentre study. Four hundred and thirty-five outpatients with the clinical diagnosis of Alzheimer's disease, received treatment with donepezil. Patients were assessed with Mini-Mental State Examination (MMSE), Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog), global rating (CIBIC) and Instrumental Activities of Daily Living (IADL) at baseline and every 6 months for a total period of 3 years. RESULTS: The mean MMSE change from baseline was positive for more than 6 months and in subgroups of patients for 12 months. After 3 years of treatment the mean change from baseline in MMSE-score was 3.8 points (95% CI, 3.0-4.7) and the ADAS-cog rise was 8.2 points (95% CI, 6.4-10.1). This is better than expected in untreated historical cohorts, and better than the ADAS-cog rise calculated by the Stern equation (15.6 points; 95% CI, 14.5-16.6). After 3 years with 38% of the patients remaining, 30% of the them were unchanged or improved in the global assessment. CONCLUSION: Three-year donepezil treatment showed a positive global and cognitive outcome in the routine clinical setting.
Asa K Wallin; Niels Andreasen; Sture Eriksson; Stellan Båtsman; Birgitta Nasman; Anne Ekdahl; Lena Kilander; Mikaela Grut; Marie Rydén; Anders Wallin; Mikael Jonsson; Hasse Olofsson; Elisabeth Londos; Carina Wattmo; Maria Eriksdotter Jonhagen; Lennart Minthon;
Related Documents :
15906058 - Alzheimer's disease and frontal variant of frontotemporal dementia-- a very brief batte...
16670248 - Neuropsychiatric symptoms in alzheimer disease and cognitively impaired, nondemented el...
23764268 - Treatment trials for post-lyme disease symptoms revisited.
18290848 - How long can patients with mild or moderate alzheimer's dementia maintain both the cogn...
12747278 - Glucocorticoid receptor up-regulation in early rheumatoid arthritis treated with low do...
3899368 - Clinical trial of nimodipine for single attacks of classic migraine.
Publication Detail:
Type:  Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't     Date:  2006-12-18
Journal Detail:
Title:  Dementia and geriatric cognitive disorders     Volume:  23     ISSN:  1420-8008     ISO Abbreviation:  Dement Geriatr Cogn Disord     Publication Date:  2007  
Date Detail:
Created Date:  2007-02-22     Completed Date:  2007-04-26     Revised Date:  2008-03-24    
Medline Journal Info:
Nlm Unique ID:  9705200     Medline TA:  Dement Geriatr Cogn Disord     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  150-60     Citation Subset:  IM    
Clinical Memory Research Unit, Department of Clinical Sciences, Malmo, Lund University, Malmo, Sweden.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Alzheimer Disease / drug therapy*
Cognition / drug effects*
Disease Progression
Indans / therapeutic use*
Longitudinal Studies
Middle Aged
Neuropsychological Tests
Nootropic Agents / therapeutic use*
Piperidines / therapeutic use*
Prospective Studies
Psychiatric Status Rating Scales
Statistics, Nonparametric
Treatment Outcome
Reg. No./Substance:
0/Indans; 0/Nootropic Agents; 0/Piperidines; 120011-70-3/donepezil

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Limitations of skin protection.
Next Document:  Carotid duplex ultrasonography during head-up tilt in patients with orthostatic hypotension.